Find and Pitch Jounalists, Get Your Story Covered

Tags: Software & Services Software Platforms IT Automation Apple cell biology, Craniofacial, developmental biology, DNA repair, genetics, oxidative stress

	Profile	Recent Articles on Subject
1	John Pinching PharmaTimes Next-gen biopharma company. La Jolla, California biopharmadrugsdevices	Oxford Drug Design achieves in vivo validation for novel cancer treatment - 16 days ago
2	Amy Baxter Pharma Voice Scientist, inventor, former pediatrician. Atlanta, Georgia pain relieftechnologyinnovation	Merck is broadening its pipeline as Keytruda’s patent cliff looms - 17 days ago Oncology, obesity and more: Where pharma R&D is headed in 2025 - about 2 months ago 2024 PharmaVoice 100s: Clinical Trial Pros - 3 months ago 3 FDA approval dates to watch in the year’s final push - 5 months ago Autobahn’s road to a breakthrough depression treatment is paved with high-profile investors - 6 months ago To overcome barriers, cell and gene therapies need outside support - 6 months ago FDA’s platform designation aims to ease R&D pain points - 8 months ago Execs from Bayer, Kite and Orca sound off on their launch strategies for cell and gene therapies - 9 months ago As AI proliferates in pharma, regulators look to catch up in clinical trials - 9 months ago Black Diamond looks to outwit cancer mutations - 11 months ago For Moderna, COVID vaccines were a ‘proof of concept’ — now comes the big test - 11 months ago
3	Meagan Parrish Pharma Voice Senior editor @industrydive. Pharma world follower. Wisconsin, USA pharmaceuticalsjournalismparenting	PharmaVoice’s Crystal Ball: The industry’s AI future - 24 days ago 3 closely watched drugs that failed in the clinic - about 2 months ago 2024 PharmaVoice 100s: Rare Disease Warriors - 3 months ago Is anyone taking the world’s priciest drugs? - 5 months ago Neuro drugs are still faltering, despite rising investment - 6 months ago Up-and-comers look for an edge in the bustling ADC field - 7 months ago Pharma’s R&D gamble: picking pipeline winners in a risky field - 8 months ago After Vyvanse patent loss, Takeda’s neuroscience division looks to enter a new era - 9 months ago Neurvati touts fresh, ‘synergistic’ investment model in neuroscience R&D - 11 months ago PharmaVoice’s Crystal Ball: What’s next in drug innovation and clinical trials - about 1 year ago PharmaVoice 100s: Clinical trial gurus - over 1 year ago 3 recent FDA adcomm rejections — and why they matter - over 1 year ago
4	Meghana Keshavan STAT News Biotech nerd and writer @statnews. biotechwriting	Merck is a new year outlier with its diabetes drug - 28 days ago
5	Ed Silverman STAT News Pharmalot columnist. Senior writer at STATnews. pharmaceutical industry	STAT+: Tuberculosis R&D funding is up, but still short of goals and dominated by a few players, report finds - about 2 months ago STAT+: FDA agrees to review a rare disease drug that its developer was about to give up on - 10 months ago STAT+: Pharmalittle: FDA approvals rebound, abortion pill orders rise, and more news - about 1 year ago
6	<em>The Scientist</em> Staff The Scientist Exploring Life, Inspiring Innovation. scienceinnovation	New Frontiers in Vaccine Development - about 2 months ago
7	Brittany Trang STAT News Health care business reporter. PhD. Indie rock fan. health carebusiness reporting	STAT+: Using AI to design small molecule drugs is tough. Here are five companies trying to crack the code - about 2 months ago
8	Jason Mast STAT News Writing about science, medicine. ScienceMedicineBusiness	STAT+: U.K. charities give $36 million to start new drugs for childhood tumors - 5 months ago
9	Ashley Gallagher, Associate Editor Pharmacy Times One of Cabra girls on GoggleboxIRL. Dublin City, Ireland televisionentertainment	Pharmacy Focus: Alzheimer Drug Pipeline Expands, Promising Therapies in Development - 5 months ago Key Market Trends for the Current Specialty Drug Pipeline - over 1 year ago
10	Allison DeAngelis STAT News Reporter at STAT. Formerly Insider, BBJ. biopharmastartupsventure capital	STAT+: Cardiovascular startup raises $260 million led by ex-Moderna execs’ new VC fund - 7 months ago

Journalists covering drug development